Angiogenesis inhibitors: Implications for combination with conventional therapies

Michele Moschetta, Marta Cesca, Francesca Pretto, Raffaella Giavazzi

Research output: Contribution to journalArticlepeer-review

Abstract

Angiogenesis is associated with tumor development and malignancy and is a validated target for cancer treatment. Preclinical and clinical evidence substantiates the feasibility of combining angiogenesis inhibitors with conventional anticancer therapy. This review discusses recent progress in combining antiangiogenic drugs, mainly acting on the VEGF/VEGFR pathway, with chemotherapy and other conventional therapies. Strategies for the optimization of combination therapy and the selection of appropriate treatment regimens are examined. As new drugs are entering clinical trials, reliable biomarkers are needed to stratify patients for antiangiogenic therapy, to identify resistant patients and to monitor response to treatment.

Original languageEnglish
Pages (from-to)3921-3931
Number of pages11
JournalCurrent Pharmaceutical Design
Volume16
Issue number35
DOIs
Publication statusPublished - 2010

Keywords

  • Angiogenesis
  • Biomarker
  • Combination Therapy
  • Resistance
  • Toxicity
  • VEGF

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'Angiogenesis inhibitors: Implications for combination with conventional therapies'. Together they form a unique fingerprint.

Cite this